Adverum Biotechnologies reported a net loss of $18.8 million, or $0.30 per share, in the second quarter of 2018 compared with a net loss of $11.4 million, or $0.27 per share, in 2017’s second quarter.
The company’s general and administrative expenses totaled $9.2 million for the quarter, an increase from 2017’s second quarter costs of $4.1 million.
Research and development expenses increased from $8.5 million to $11.2 million in the quarter, which the company attributed to an increase in research and development activities.
In July, Adverum submitted an investigational new drug
Uncategorized